Literature DB >> 6579344

Energy-dependent reduced drug binding as a mechanism of Vinca alkaloid resistance in human leukemic lymphoblasts.

W T Beck, M C Cirtain, J L Lefko.   

Abstract

We studied the accumulation of [3H]vinblastine (VLB) by lines of CCRF-CEM cultured human leukemic lymphoblasts that were either sensitive or resistant to the drug. Neither cell line metabolized VLB, nor selectively retained any radioactive impurities. There was an apparent "instantaneous" accumulation of VLB by cells of both lines, resulting in cell to medium ratios greater than 1.0 within 1 sec after drug addition. Experiments between 0 and 60 sec revealed that the presumed undirectional initial rate of VLB accumulation by resistant cells, termed CEM/VLB100, was about one-half that of sensitive CEM cells. In experiments carried out over 60 min, the VLB-resistant cells accumulated considerably less [3H]VLB than did the sensitive cells. Drug accumulation by both cell lines was temperature-sensitive, since incubation of cells at 4 degrees resulted in only minimal uptake beyond that observed at zero time. CEM/VLB100 cells retained less drug than did CEM cells, apparently because of a larger fraction of readily releasable VLB compared with CEM cells. The accumulation of VLB by either cell line was related in part to cellular levels of ATP. Although depletion of ATP was associated with decreased accumulation of VLB by CEM cells, it was related to enhanced drug accumulation by CEM/VLB100 cells. Restoration of ATP levels to near control values by addition of glucose also had opposite effects on the two cell lines, causing further accumulation of VLB by the sensitive line but leading to apparent drug efflux from the resistant line. Potentially competing substrates (VM-26, colchicine, daunorubicin, and doxorubicin) failed to block this glucose-mediated release of VLB from the CEM/VLB100 cells. In experiments with energy-depleted CEM/VLB100 cells preloaded with VLB and then incubated in drug-free medium, initial drug loss was shown to be independent of cellular metabolism, being roughly the same for both metabolically intact and metabolically depleted cells. Glucose (energy) was required only for subsequent release of what appeared to be a more tightly bound cell-associated fraction of VLB. Results of zero-time binding studies tended to confirm that VLB binding by resistant cells has two components, one requiring and the other not requiring metabolic energy. Differences in the proportions of these two components between the sensitive and resistant cells suggest a mechanism for resistance to VLB and similar compounds.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6579344

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  11 in total

1.  Intracellular pH and the control of multidrug resistance.

Authors:  S Simon; D Roy; M Schindler
Journal:  Proc Natl Acad Sci U S A       Date:  1994-02-01       Impact factor: 11.205

2.  Comparative uptake, retention and action of vincristine, vinblastine and vindesine on murine leukaemic lymphoblasts sensitive and resistant to vincristine.

Authors:  M P Rivera-Fillat; J Pallarés-Trujillo; C Domènech; M R Grau-Oliete
Journal:  Br J Pharmacol       Date:  1988-04       Impact factor: 8.739

3.  Saturable process involved in active efflux of vincristine as a mechanism of multidrug resistance in P388 leukemia cells.

Authors:  T Watanabe; M Inaba; Y Sugiyama
Journal:  Pharm Res       Date:  1989-08       Impact factor: 4.200

4.  Relationship between the cellular accumulation and the cytotoxicity of S12363, a new Vinca alkaloid derivative.

Authors:  A Pierré; V Pérez; S Léonce; J A Boutin; D Saint-Dizier; P Hautefaye; G Lavielle; G Atassi
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

5.  Allelism of SNQ1 and ATR1, genes of the yeast Saccharomyces cerevisiae required for controlling sensitivity to 4-nitroquinoline-N-oxide and aminotriazole.

Authors:  P Gömpel-Klein; M Brendel
Journal:  Curr Genet       Date:  1990-07       Impact factor: 3.886

6.  Subcellular localisation of the antitumour drug mitoxantrone and the induction of DNA damage in resistant and sensitive human colon carcinoma cells.

Authors:  M E Fox; P J Smith
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

7.  Decreased resistance to N,N-dimethylated anthracyclines in multidrug-resistant Friend erythroleukemia cells.

Authors:  A Schaefer; J Westendorf; K Lingelbach; C A Schmidt; D L Mihalache; A Reymann; H Marquardt
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

8.  Overexpression of the cystic fibrosis transmembrane conductance regulator in NIH 3T3 cells lowers membrane potential and intracellular pH and confers a multidrug resistance phenotype.

Authors:  L Y Wei; M J Stutts; M M Hoffman; P D Roepe
Journal:  Biophys J       Date:  1995-09       Impact factor: 4.033

9.  Cell biological mechanisms of multidrug resistance in tumors.

Authors:  S M Simon; M Schindler
Journal:  Proc Natl Acad Sci U S A       Date:  1994-04-26       Impact factor: 11.205

10.  Modulation of vinblastine sensitivity by dipyridamole in multidrug resistant fibrosarcoma cells lacking mdr1 expression.

Authors:  D R Shalinsky; M L Slovak; S B Howell
Journal:  Br J Cancer       Date:  1991-10       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.